FibroBiologics to Present at the DealFlow Discovery Conference
FibroBiologics, Inc. (FBLG)
Company Research
Source: GlobeNewswire
HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the DealFlow Discovery Conference taking place January 28-29, 2026, at the Borgata in Atlantic City, New Jersey. FibroBiologics will deliver a company presentation at 11:30 a.m. ET on Thursday, January 29 and will be available for one-on-one investor meetings throughout the event. For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibrobl
Show less
Read more
Impact Snapshot
Event Time:
FBLG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBLG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBLG alerts
High impacting FibroBiologics, Inc. news events
Weekly update
A roundup of the hottest topics
FBLG
News
- FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for CachexiaGlobeNewswire
- FibroBiologics CEO Issues Letter to ShareholdersGlobeNewswire
- FibroBiologics (NASDAQ:FBLG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.MarketBeat
- FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment ConferenceGlobeNewswire
- FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease [Yahoo! Finance]Yahoo! Finance
FBLG
Earnings
- 5/14/25 - Miss
FBLG
Sec Filings
- 2/6/26 - Form 8-K
- 1/2/26 - Form 8-K
- 12/31/25 - Form EFFECT
- FBLG's page on the SEC website